Similarly, ctDNA-detected KEAP1 and STK11 co-mutations in advanced NSCLC were found to be associated with a lower objective response rate (12% vs. 38%, p = 0.01) and shorter median PFS (2.8 vs. 6.7 months, p = 0.005) compared to wild-type patients [73]. The gene discussed is STK11; the disease is non-small cell lung carcinoma.